Analyst Price Targets — SVRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 16, 2026 3:22 pm | — | William Blair | $10.00 | $5.17 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date' |
| December 23, 2025 11:42 am | — | Oppenheimer | $10.00 | $6.47 | StreetInsider | Savara (SVRA) PT Raised to $10 at H.C. Wainwright |
| December 23, 2025 11:42 am | — | UBS | $10.00 | $6.47 | StreetInsider | Savara (SVRA) PT Raised to $10 at H.C. Wainwright |
| October 23, 2025 8:42 am | — | JMP Securities | $11.00 | $4.24 | TheFly | Savara price target raised to $11 from $8 at Citizens JMP |
| September 9, 2025 11:07 am | — | Guggenheim | $11.00 | $3.82 | TheFly | Savara price target raised to $11 from $8 at Guggenheim |
| August 15, 2025 1:07 pm | Andrew Fein | H.C. Wainwright | $5.00 | $3.09 | TheFly | H.C. Wainwright upgrades Savara to Buy on resubmission prospects |
| August 13, 2024 6:01 am | Jonathan Wolleben | JMP Securities | $4.50 | $2.04 | TheFly | Savara price target lowered to $9 from $10 at JMP Securities |
| June 27, 2024 8:56 am | Vamil Divan | Guggenheim | $5.00 | $1.92 | TheFly | Savara price target raised to $10 from $8 at Guggenheim |
| June 27, 2024 6:03 am | Andrew Fein | H.C. Wainwright | $5.00 | $1.92 | TheFly | Savara price target raised to $10 from $6 at H.C. Wainwright |
| June 27, 2024 5:38 am | Jonathan Wolleben | JMP Securities | $5.00 | $1.98 | StreetInsider | Savara (SVRA) PT Raised to $10 at JMP Securities |
Latest News for SVRA
394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted average price of around $5.68 per share. This transaction represented 42.40% of the executive's total common stock holdings pre-transaction.
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to…
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be…
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY. The live webcast and subsequent replay…
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, with MOLBREEVI targeting autoimmune PAP. SVRA's cash runway extends into H2 2027, bolstered by $203M in liquidity and up to $150M in non-dilutive capital upon FDA approval. Regulatory momentum is strong: MOLBREEVI has Priority Review, with a PDUFA date set for November 22, 2026, and positive Phase 3 data supporting…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SVRA.
U.S. House Trading
No House trades found for SVRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.